Journal
CARDIOVASCULAR RESEARCH
Volume 73, Issue 4, Pages 657-666Publisher
OXFORD UNIV PRESS
DOI: 10.1016/j.cardiores.2006.12.009
Keywords
calmodulin kinase II; arrhythmias
Categories
Funding
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062494, R01HL096652, P01HL046681, R01HL070250] Funding Source: NIH RePORTER
- NHLBI NIH HHS [HL62494, R01 HL096652, HL070250, HL046681] Funding Source: Medline
Ask authors/readers for more resources
The multifunctional Ca2+ calmodulin-dependent protein kinase II (CaMKII) has emerged as a pro-arrhythmic signaling molecule. CaMKII can participate in arrhythmia signaling by effects on ion channel proteins, intracellular Ca2+ uptake and release, regulation of cell death, and by activation of hypertrophic signaling pathways. The pleuripotent nature of CaMKII is reminiscent of another serine-threonine kinase, protein kinase A (PKA), which shares many of the same protein targets and is the downstream kinase most associated with beta-adrenergic receptor stimulation. The ability of CaMKII to localize and coordinate activity of multiple protein targets linked to Ca2+ signaling set CaMKII apart from other traditional arrhythmia drug targets, such as ion channel proteins. This review will discuss some of the biology of CaMKII and focus on work that has been done on molecular, cellular, and whole animal models that together build a case for CaMKII as a pro-arrhythmic signal and as a potential therapeutic target for arrhythmias and structural heart disease. (c) 2007 European Society of Cardiology. Published by Elsevier B.V All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available